Enbrel CHF follow-up data

Immunex (IMNX) presented 6-month follow-up data from 12 congestive heart failure (CHF) patients in a 47-patient Phase I study showing that its Enbrel etanercept soluble TNF receptor was well-tolerated (see BioCentury, March 15, 1999). The 12 patients, who were treated for 9 months, showed sustained clinical improvement while 31 patients who discontinued treatment at 3 months did not experience rebound of their disease. ...